Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Commercial plans.

When does this change take effect?

This change is effective Apr 1, 2026.

Back to dashboard

CommercialCoverageLow impact

08.02.34, Axatilimab-csfr (Niktimvo™) for Intravenous Use

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new pharmacy policy for Axatilimab-csfr (Niktimvo™) intravenous use has been reissued for commercial plans. This appears to be a policy reissuance or update affecting coverage criteria for this specialty medication.

Action Required

Action needed

By April 1, 2026: Review updated coverage criteria for Axatilimab-csfr (Niktimvo™) intravenous infusions. Billing team should access the full policy at the provided URL to understand any changes to prior authorization requirements, coverage limitations, or documentation needs for this specialty pharmacy benefit.

Related policy hubs

Independence Blue Cross policies Oncology Hematology